{"groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"FG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"FG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"FG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"FG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"FG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"FG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"FG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"FG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"FG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"FG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"FG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"17"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"5"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"17"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"27"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"26"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"27"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"26"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"28"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant with breast cancer was screened shortly after Cohort 5 (Breast Cancer) had been closed. This participant was allowed to enter the study in Cohort 7: Other BRAF V600-positive tumors. For analysis purposes Cohort 7 was split into sub-cohorts for indications with sufficient participants."}